<DOC>
	<DOCNO>NCT00744107</DOCNO>
	<brief_summary>To demonstrate safety efficacy Cobra Cobalt Super Alloy Balloon-Expandable Coronary Stent System treatment de novo restenotic ( previously unstented ) lesion native coronary artery subject coronary artery disease ( CAD ) reference vessel diameter ( RVD ) 2.5 - 4.0 mm lesion length ≤ 26 mm amenable percutaneous coronary intervention ( PCI ) single stent subject symptomatic ischemic heart disease .</brief_summary>
	<brief_title>Cobra II Study : Use Cobra™ Cobalt Super Alloy Coronary Stent System Treatment Coronary Artery Disease</brief_title>
	<detailed_description>Safety Efficacy demonstrate rate Target vessel failure ( TVF ) , define cardiac death , target vessel myocardial infarction ( MI ) [ Q wave non-Q wave ] , clinically driven target vessel revascularization ( TVR ) percutaneous surgical method within 270 day post-stent placement procedure . Additionally , Major Adverse Cardiac Events ( MACE ) 30 , 180 270 day define composite all-cause death , myocardial infarction ( MI ) ( Q wave non-Q wave ) , emergent bypass surgery , clinically drive target lesion revascularization ( TLR ) [ percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) ] document .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>The subject ≥ 18 year old ; Subject eligible percutaneous coronary intervention ( PCI ) , stent placement , emergent coronary artery bypass graft ( CABG ) surgery ; Subject clinical evidence ischemic heart disease , stable unstable angina silent ischemia ; The subject document leave ventricular ejection fraction ( LVEF ) ≥ 30 % ; The subject legal representative inform clinical study require followup procedure must provide write informed consent use form review approved Institutional Review Board/Ethics Committee ( IRB/EC ) clinical site ; Female subject childbearing potential must negative pregnancy test within 7 day treatment ; Subject must agree comply require followup procedure ( include antiplatelet regimen ) best ability , geographically available study followup procedures visit know medical condition precludes completion require followup visit ; The lesion either de novo restenotic ( previously unstented ) nature , locate native coronary artery AND ≥ 50 % &lt; 100 % stenosed visual estimate online QCA ; The target vessel reference diameter ≥ 2.5mm ≤ 4mm visual estimate appropriate treatment available stent diameter 2.5 mm , 4.0 mm ; The lesion length ≤ 26 mm able accommodate placement single stent ; The target lesion minimum 15 mm previously place stent ; AND The target vessel must Thrombolysis In Myocardial Infarction ( TIMI ) flow ≥ 2 The subject know hypersensitivity contraindication aspirin , heparin bivalirudin , ticlopidine clopidogrel , cobalt , nickel , chromium , molybdenum , sensitivity contrast medium , adequately premedicated ; A platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , WBC &lt; 3,000 cells/mm³ ; A creatinine level &gt; 2.5 mg/dL within 7 day prior index procedure ; Evidence acute myocardial infarction ( MI ) within 72 hour intend treatment ( define : Q wave ( QWMI ) elevation creatine kinase myocardialband ( CKMB ) isoenzyme elevate Institution 's upper limit normal ; Any previous PCI ( without stent ) target vessel within 30 day prior index procedure ; Previous stent placement anywhere target lesion ; Previous drug elute stent ( DES ) deployment anywhere target vessel ; The subject require staged procedure nontarget vessel within 30 day postprocedure ; The subject require staged procedure target vessel within 9 month postprocedure ; The target lesion require treatment device PTCA prior stent placement ( include , limited , cut balloon , directional coronary atherectomy , excimer laser , rotational atherectomy , thrombectomy , etc . ; History stroke transient ischemic attack ( TIA ) within previous 6 month ; Active peptic ulcer upper gastrointestinal ( GI ) bleed within previous 6 month ; History bleed diathesis coagulopathy refuse blood transfusion ; A known concurrent medical condition result life expectancy le 12 month ; Any previous plan treatment target vessel antirestenotic therapy include , limited brachytherapy ; The subject currently participate another investigational device drug study complete primary endpoint ( ) followup phase study least 30 day prior enrollment trial ; interfere current trial endpoint ; subject previously enrol study ; The subject know medical condition cause noncompliant study protocol confound data interpretation ; The target vessel evidence thrombus lesion &gt; 60 % stenosis visual estimate online QCA ; Target vessel exhibit multiple lesion great 60 % diameter stenosis outside range 5 mm proximal distal target lesion base visual estimate online QCA ; The target vessel evidence ( visual QCA ) excessive tortuosity ( two 90° bend prior target lesion ) severely calcify ; OR The target lesion unprotected leave main , involve side branch vessel diameter &gt; 2.0 mm aortoostial location</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Ischemic coronary artery disease native coronary artery</keyword>
	<keyword>Single stent</keyword>
	<keyword>RVD 2.5- 4.0mm</keyword>
	<keyword>Lesion length 26mm</keyword>
	<keyword>de novo previously unstented lesion</keyword>
</DOC>